Intravenous tirofiban following endovascular therapy for patients with acute large vessel occlusion stroke

作者：Lina Zheng, Yaqi Liu, Ximing Nie, Hongyi Yan, Weibin Gu, Xin Liu, Wanying Duan, Zhe Zhang, Jingyi Liu, Yufei Wei, Miaowen Wen, Zhonghua Yang, Yuesong Pan, Xinyi Leng, Zhongrong Miao, Liping Liu · 发表于：International Journal of Stroke · 年份：2025 · DOI：10.1177/17474930251386577 · 被引用次数：2 · 研究领域：Acute Ischemic Stroke Management、Intracerebral and Subarachnoid Hemorrhage Research、S100 Proteins and Annexins

BACKGROUND: The role of intravenous (IV) tirofiban administered following endovascular therapy (EVT) for acute ischemic stroke (AIS) due to large vessel occlusion (LVO) remains uncertain. AIMS: To investigate the associations of IV tirofiban following EVT with clinical outcomes in patients with acute LVO stroke and to determine whether the associations differ between anterior-circulation stroke (ACS) and posterior-circulation stroke (PCS). METHODS: In this prospective, national, multicenter registry, patients with AIS due to intracranial LVO who underwent EVT within 24 h of onset were enrolled and categorized into IV tirofiban and no-IV tirofiban groups. The primary outcome was functional independence at 90 days, defined as a modified Rankin Scale of 0-2. Secondary outcomes included the distribution of 90-day mRS, independent ambulation, symptomatic intracranial hemorrhage (sICH), early neurological deterioration (END), and 90-day mortality. Analyses included univariate and multivariable logistic regression and propensity score matching (PSM, 1:1 ratio). RESULTS: Among 1836 eligible patients (1342 ACS; 494 PCS), 362 (19.7%) received IV tirofiban following EVT. After PSM, 720, 498, and 196 patients were included in the entire, ACS, and PCS cohorts, respectively. In the ACS cohort, IV tirofiban was associated with higher odds of functional independence (57.0% vs. 43.8%; adjusted odds ratio (aOR) 1.55, 95% confidence interval (CI) = 1.08-2.22; P = 0.02) and a favorable shift in ...